Cover Image
市場調查報告書

離子通道型麩胺酸受體NMDA 2B:開發中產品分析

Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365747
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
離子通道型麩胺酸受體NMDA 2B:開發中產品分析 Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 52 Pages
簡介

本報告提供以離子通道型麩胺酸受體NMDA 2B為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

離子通道型麩胺酸受體NMDA 2B 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • BioCrea GmbH
  • Bristol-Myers Squibb Company
  • Cerecor Inc.
  • Johnson & Johnson
  • Luc Therapeutics, Inc.
  • NeurOp, Inc
  • Novartis AG
  • UCB S.A.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0191TDB

Summary

Global Markets Direct's, 'Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Pipeline Review, H1 2016', provides in depth analysis on Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted pipeline therapeutics.

The report provides comprehensive information on the Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B)
  • The report reviews Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) Overview
  • Therapeutics Development
    • Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Products under Development by Stage of Development
    • Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Products under Development by Therapy Area
    • Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Products under Development by Indication
  • Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Products under Development by Companies
  • Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Companies Involved in Therapeutics Development
    • BioCrea GmbH
    • Bristol-Myers Squibb Company
    • Cerecor Inc.
    • Johnson & Johnson
    • Luc Therapeutics, Inc.
    • NeurOp, Inc
    • Novartis AG
    • UCB S.A.
  • Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Drug Profiles
    • CERC-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EVT-100 Series - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EVT-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NP-10679 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NP-11948 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • radiprodil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize NMDA2B for Cognitive Impairment Associated With Schizophrenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize NMDA Receptor 2B for Depression and Major Depressive Disorder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize NR2B for Depression - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize NR2B for Neuropathic Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Dormant Projects
  • Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Discontinued Products
  • Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Featured News & Press Releases
    • Jan 19, 2016: Cerecor Announces Publication Describing Antidepressant Activity of CERC-301 in Preclinical Model
    • Sep 03, 2015: Cerecor Initiates Phase 2 Study for CERC-301, an Antidepressant Product Candidate with Potential for Rapid Onset of Effect
    • Mar 20, 2015: Cerecor Provides Update on CERC-301 Development in Major Depressive Disorder
    • Oct 03, 2014: Cerecor to Present at 13th Annual BIO Investor Forum
    • Oct 02, 2014: NeurOp Receives Milestone Payment as Bristol-Myers Squibb Nominates NMDA Receptor Compound as Drug Development Candidate
    • Dec 02, 2013: MedAvante Central Ratings Selected For Cerecor Investigational MDD Study
    • Nov 25, 2013: Cerecor Receives Fast Track Designation for CERC-301 for the Treatment of Major Depressive Disorder
    • Nov 08, 2013: Cerecor Announces Initiation of Phase 2 Study for CERC-301, an Oral Rapid-acting Antidepressant Candidate
    • Jun 28, 2010: Forest And Gedeon Richter Announce Phase II Study Results Of Radiprodil For Treatment Of Diabetic Peripheral Neuropathic Pain
    • Mar 11, 2010: Evotec Completes Clinical Part Of First Phase I Study Of EVT 103
    • Sep 08, 2009: Evotec Starts Phase I With EVT 103, An NR2B-Selective NMDA Receptor Antagonist
    • Nov 29, 2005: Gedeon Richter And Forest Laboratories Expand Relationship With Two New Collaborations For CNS Compounds
    • Mar 24, 2004: Evotec Neurosciences License NMDA Receptor NR2B Subunit Selective Antagonists From Roche
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by BioCrea GmbH, H1 2016
  • Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Pipeline by Cerecor Inc., H1 2016
  • Pipeline by Johnson & Johnson, H1 2016
  • Pipeline by Luc Therapeutics, Inc., H1 2016
  • Pipeline by NeurOp, Inc, H1 2016
  • Pipeline by Novartis AG, H1 2016
  • Pipeline by UCB S.A., H1 2016
  • Dormant Projects, H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top